CRP and COVID-19: Thus, therapeutic anticoagulation was continued after hospitalization.22, 29, 33, 35, 41, 46In 13 studies, the decision was left to the treating physicians and was based on clinical (e.g., age, body mass index, and comorbidities), laboratory (e.g., D-dimer level and C-reactive protein), and radiological findings that indicated a higher risk of mortality.7, 28, 30, 32, 36, 40, 42, 56In six studies, anticoagulation doses were based on locally or nationally adapted thromboprophylaxis guidelines4, 8, 23, 34, 37, 44that continued to evolve as more literature became available on COVID-19.